anti-IL-17 human monoclonal antibodies immortalized human B-cell technology (AIMM Therapeutics)
N/A
Report date: 2025/02/01 20:00:06
Base Information
Drug Nameanti-IL-17 human monoclonal antibodies immortalized human B-cell technology (AIMM Therapeutics)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[1] N/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAimm Therapeutics
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesAimm Therapeutics
Active IndicationsN/A
Inactive Indications +[1] N/A
Other Information
ATC CodeN/A
Related LinksN/A